China's 3SBio in-licenses second PharmAbcine mAb

PharmAbcine Inc. (Daejon, South Korea) granted 3SBio Inc. (Shenyang, China) an exclusive license to develop DIG-KT ( TRPH 011) in greater

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE